These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20095429)

  • 1. [Antigenic composition and serologic characteristics of domestic acellular pertussis vaccine].
    Zaĭtsev EM; Poddubikov AV; Britsina MV; Mertsalova NU; Bazhanova IG; Ozeretskovskaia MN; Nazirov MP; Mazurova IK; Petrova MS; Popova OP; Zakharova NS
    Zh Mikrobiol Epidemiol Immunobiol; 2009; (6):76-9. PubMed ID: 20095429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women.
    Wanlapakorn N; Maertens K; Chaithongwongwatthana S; Srimuan D; Suratannon N; Vongpunsawad S; Tran TMP; Hens N; Van Damme P; Locht C; Poovorawan Y; Leuridan E
    Vaccine; 2018 Mar; 36(11):1453-1459. PubMed ID: 29426663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.
    Ladhani SN; Andrews NJ; Southern J; Jones CE; Amirthalingam G; Waight PA; England A; Matheson M; Bai X; Findlow H; Burbidge P; Thalasselis V; Hallis B; Goldblatt D; Borrow R; Heath PT; Miller E
    Clin Infect Dis; 2015 Dec; 61(11):1637-44. PubMed ID: 26374816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years.
    Frampton JE; Keam SJ
    Paediatr Drugs; 2006; 8(3):189-95; discussion 196. PubMed ID: 16774298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.
    Knuf M; Zepp F; Meyer C; Grzegowski E; Wolter J; Riffelmann M; Wirsing von König CH
    Vaccine; 2006 Mar; 24(12):2043-8. PubMed ID: 16356597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological responses to infection with B. pertussis.
    Giammanco A; Taormina S; Genovese M; Mangiaracina G; Giammanco G; Chiarini A
    Dev Biol Stand; 1997; 89():213-20. PubMed ID: 9272353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis.
    Wei SC; Tatti K; Cushing K; Rosen J; Brown K; Cassiday P; Clark T; Olans R; Pawloski L; Martin M; Tondella ML; Martin SW
    Clin Infect Dis; 2010 Aug; 51(3):315-21. PubMed ID: 20578875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of magnetic bead pentaplex immunoassay for simultaneous quantification of murine serum IgG antibodies to acellular pertussis, diphtheria and tetanus antigens used in combination vaccines.
    Kadam L; Patel K; Gautam M; Thorat S; Kale P; Ghule AK; Gairola A; Rao H; Shinde Y; Shaligram U; Gairola S
    Methods; 2019 Apr; 158():33-43. PubMed ID: 30690077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
    Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preclinical studies of an adsorbed diphtheria-tetanus-pertussis vaccine (ADTP-vaccine) with acellular pertussis component].
    Zaĭtsev EM; Britsina MV; Bazhanova IG; Mertsalova NU; Ozeretskovskaia MN; Ermolova EV; Plekhanova NG; Mikhaĭlova NA; Kolyshkin VA; Zverev VV
    Zh Mikrobiol Epidemiol Immunobiol; 2013; (6):44-9. PubMed ID: 24605674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.
    Barug D; Pronk I; van Houten MA; Versteegh FGA; Knol MJ; van de Kassteele J; Berbers GAM; Sanders EAM; Rots NY
    Lancet Infect Dis; 2019 Apr; 19(4):392-401. PubMed ID: 30938299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunogenicity and reactogenicity of acellular pertussis vaccines intended for adolescent and adults].
    Zawadka M; Lutyńska A
    Przegl Epidemiol; 2012; 66(1):99-105. PubMed ID: 22708307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An acellular pertussis vaccine based on the natural complex of antigens isolated from the supernatant of a synthetic culture medium].
    Zakharova NS; Remova TN; Bazhanova IG; Ozeretskovskaia MH; Britsina MV; Shmeleva EI; Mertsalova NU; Ermolova EI; Sukhinova EE; Bulk VF; Sirotinskiĭ AV; Poluiianova AG; Sviridov VV; Vartanian IuP
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):67-70. PubMed ID: 9304334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic value of IgG, IgA, and IgM to Bordetella pertussis antigens in patients with pertussis].
    Zaĭtsev EM; Mazurova IL; Petrova MS; Krasnoproshina LI; Zakharova NS
    Zh Mikrobiol Epidemiol Immunobiol; 2008; (6):23-6. PubMed ID: 19186540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.